CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of t cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas

mAbs

Volumn 6, Issue 6, 2014, Pages 1571-1584

  Oberst, Michael D ^a   Fuhrmann, Stacy ^a   Mulgrew, Kathy ^a   Amann, Maria ^a,b   Cheng, Lily ^a   Lutterbuese, Petra ^b   Richman, Laura ^a   Coats, Steve ^a   Baeuerle, Patrick A ^b   Hammond, Scott A ^a  

^a MedImmun LLC ^*  (Switzerland)

^b Amgen Research GmbH   (Germany)

Author keywords

AMG 211; Bispecific antibody; CD3; CEA; MEDI 565; MT111; T cells

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CD3 ANTIGEN; CD69 ANTIGEN; GRANZYME B; INTERLEUKIN 2 RECEPTOR ALPHA; K RAS PROTEIN; MEDI 565; PERFORIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; UNCLASSIFIED DRUG; PROTEIN BINDING;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CD3+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG PROTEIN BINDING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MALE; NONHUMAN; PANCREAS CARCINOMA; PROTEIN EXPRESSION; SOMATIC MUTATION; T LYMPHOCYTE ACTIVATION; ADENOCARCINOMA; ANIMAL; CELL CULTURE; CHO CELL LINE; COLORECTAL NEOPLASMS; CRICETULUS; CYTOTOXICITY; DRUG EFFECTS; DRUG SCREENING; GENETICS; HAMSTER; HELA CELL LINE; HT 29 CELL LINE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MUTATION; NEOPLASMS; SCID MOUSE; T LYMPHOCYTE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CELLS, CULTURED; CHO CELLS; COLORECTAL NEOPLASMS; CRICETINAE; CRICETULUS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HELA CELLS; HT29 CELLS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MICE, SCID; MUTATION; NEOPLASMS; PROTEIN BINDING; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920833141     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/19420862.2014.975660     Document Type: Article

References (81)

1. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009; 101:465-72; PMID:19603024; http://dx.doi.org/ 10.1038/sj.bjc.6605164
2. AmericanCancerSociety. Colorectal Cancer Facts & Figures 2011-2013. Atlanta, GA: American Cancer Society; 2011; 1-30.
3. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318:1108-13; PMID:17932254; http://dx.doi.org/10.1126/science.1145720
4. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/ NEJMoa0804385
5. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemother-apy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753-62; PMID:20619739; http://dx.doi.org/10.1016/ S1470-2045(10)70130-3
6. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wildtype KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924-30; PMID:19884556; http://dx.doi. org/10.1200/JCO.2008.21.6796
7. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56:892-8; PMID:8631030
8. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005; 23:7518-28; PMID:16172461; http://dx.doi. org/10.1200/JCO.2005.00.471
9. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9:701-13; PMID:19693097
10. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, et al. PIK3CA mutationPTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68:1953-61; PMID:18339877; http://dx.doi. org/10.1158/0008-5472.CAN-07-5659
11. Chen J, Huang XF, Katsifis A. Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. J Cell Biochem 2010; 111:1082-6; PMID:21053280; http://dx.doi.org/10.1002/ jcb.22905
12. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705-12; PMID:19001320; http://dx.doi.org/ 10.1200/JCO.2008.18.0786
13. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6:519-27; PMID:19636327; http://dx.doi.org/10.1038/nrclinonc.2009.111
14. Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 2010; 16:2921-6; PMID:20460490; http://dx.doi.org/10.1158/1078-0432.CCR-09-2029
15. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116
16. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RASRAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643-8; PMID:17363584; http://dx.doi.org/10.1158/0008-5472.CAN-06-4158
17. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97:1139-45; PMID:17940504; http://dx.doi.org/10.1038/sj. bjc.6604009
18. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-9; PMID:18202412; http://dx.doi.org/10.1200/ JCO.2007.12.5906
19. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, et al. PI3KCAPTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009; 20:84-90; PMID:18669866; http://dx.doi.org/10.1093/annonc/ mdn541
20. Li R SP, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M, Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998; 16:3269-77; PMID:9681825; http://dx.doi.org/ 10.1038/sj.onc.1201867
21. Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP, Johnston PG. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 2002; 62:2644-9; PMID:11980662
22. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263-9; PMID:10430607; http://dx.doi.org/ 10.1172/JCI6863
23. Goff BA, Ries JA, Els LP, Coltrera MD, Gown AM. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and sec-ond-look procedure. Gynecol Oncol 1998; 70:378-85; PMID:9790791; http://dx.doi.org/10.1006/ gyno.1998.5094
24. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56:689-93; PMID:8630996
25. Marx D, Meden H, Ziemek T, Lenthe T, Kuhn W, Schauer A. Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer 1998; 34:845-50; PMID:9797696; http://dx.doi.org/ 10.1016/S0959-8049(97)10169-1
26. Mayr D, Pannekamp U, Baretton GB, Gropp M, Meier W, Flens MJ, Scheper R, Diebold J. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract 2000; 196:469-75; PMID:10926324; http://dx.doi.org/ 10.1016/S0344-0338(00)80048-5
27. Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S, Naccarato AG, Genazzani AR, Bevilacqua G, Cavazzana AO. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinumbased chemotherapy and long-term clinical outcome. Anticancer Res 2006; 26:687-93; PMID:16739339
28. Lavarino C, Delia D, Di Palma S, Zunino F, Pilotti S. p53 in drug resistance in ovarian cancer. Lancet 1997; 349:1556; PMID:9167490; http://dx.doi.org/ 10.1016/S0140-6736(05)62140-X
29. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997; 75:230-5; PMID:9010031; http://dx. doi.org/10.1038/bjc.1997.38
30. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, et al. p53 gene status and response to plati-numpaclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000; 18:3936-45; PMID:11099323
31. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-6; PMID:19188670; http://dx. doi.org/10.1200/JCO.2009.21.9170
32. Talmadge JE, Donkor M, Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 2007; 26:373-400; PMID:17717638; http://dx. doi.org/10.1007/s10555-007-9072-0
33. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/ science.1203486
34. Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 2010; 10:1019-35; PMID:20415597; http://dx.doi.org/10.1517/14712598.2010.482207
35. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69:4941-4; PMID:19509221; http://dx.doi.org/ 10.1158/0008-5472.CAN-09-0547
36. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013; 17:385-92; PMID:23623807; http://dx.doi.org/ 10.1016/j.cbpa.2013.03.029
37. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005; 10:1237-44; PMID:16213416; http://dx.doi.org/ 10.1016/S1359-6446(05)03554-3
38. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007; 30:798-807; PMID:18049331; http://dx.doi.org/10.1097/ CJI.0b013e318156750c
39. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43:763-71; PMID:16360021; http://dx.doi.org/ 10.1016/j.molimm.2005.03.007
40. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115:98-104; PMID:15688411; http://dx.doi.org/10.1002/ijc.20908
41. Molhoj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA. CD19-CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 2007; 44:1935-43; PMID:17083975; http://dx.doi. org/10.1016/j.molimm.2006.09.032
42. Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, Mangold S, Rau D, Volkland J, Pflanz S, et al. Antitumor activity of an EpCAMCD3-bispecific BiTE antibody during longterm treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 2009; 32:452-64; PMID:19609237; http://dx.doi.org/ 10.1097/CJI.0b013e3181a1c097
43. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; http://dx.doi.org/ 10.1126/science.1158545
44. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011; 25:181-4; PMID:20944674; http://dx.doi.org/ 10.1038/leu.2010.239
45. Goebeler M, Viardot A, Noppeney R, Krause S, Mackensen A, Rupertus K, Kanz L, Knop S, Topp M, Scheele J, et al. Blinatumomab (CD3CD19 BiTE antibody) results in a high response rate in patients with relapsed non-Hodgkin lymphoma (NHL) including MCL and DLBCL. Ann Oncol 2011; 22 (Supplement 4):iv104-iv5
46. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gokbuget N, Neumann S, Goebeler M, Viardot A, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119:6226-33; PMID:22592608; http://dx.doi.org/ 10.1182/blood-2012-01-400515
47. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011; 317:1255-60; PMID:21419116; http://dx.doi.org/10.1016/j.yexcr. 2011.03.010
48. Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120:5185-7; PMID:23024237; http://dx. doi.org/10.1182/blood-2012-07-441030
49. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; http://dx.doi.org/ 10.1200/JCO.2010.32.7270
50. Haas C, Krinner E, Brischwein K, Hoffmann P, Lutterbuse R, Schlereth B, Kufer P, Baeuerle PA. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009; 214:441-53; PMID:19157637; http://dx.doi.org/10.1016/j. imbio.2008.11.014
51. Witthauer J, Schlereth B, Brischwein K, Winter H, Funke I, Jauch KW, Baeuerle P, Mayer B. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110. Breast Cancer Res Treat 2009; 117:471-81; PMID:18819003; http://dx.doi.org/10.1007/s10549-008-0185-0
52. Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S, Ruttinger D, Majdoub MW, Sharma S, Kufer P, Raum T, et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAMCD3-bispecific antibody engaging human T cells. PLoS One 2010; 5:e13474; PMID:20976159; http://dx.doi.org/ 10.1371/journal.pone.0013474
53. Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behe M, Markus PM, Gratz S, Angerstein C, Brittinger G, Becker H, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002; 94:1373-81; PMID:11877768; http://dx.doi. org/10.1002/cncr.10308
54. Granowska M, Britton KE, Mather SJ, Morris G, Ellison D, Soobramoney S, Talbot IC, Northover JM. Radioimmunoscintigraphy with technetium-99m labelled monoclonal antibody, 1A3, in colorectal cancer. Eur J Nucl Med 1993; 20:690-8; PMID:8404956; http://dx.doi.org/10.1007/BF00181760
55. Mayer A, Tsiompanou E, O'Malley D, Boxer GM, Bhatia J, Flynn AA, Chester KA, Davidson BR, Lewis AA, Winslet MC, et al. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 2000; 6:1711-9; PMID:10815889
56. Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 2002; 87:600-7; PMID:12237768; http://dx.doi.org/10.1038/sj. bjc.6600517
57. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9:67-81; PMID:10202129; http:// dx.doi.org/10.1006/scbi.1998.0119
58. Sack TL, Gum JR, Low MG, Kim YS. Release of carcinoembryonic antigen from human colon cancer cells by phosphatidylinositol-specific phospholipase C. J Clin Invest 1988; 82:586-93; PMID:3042807; http:// dx.doi.org/10.1172/JCI113636
59. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg 1998; 228:59-63; PMID:9671067; http://dx.doi.org/ 10.1097/00000658-199807000-00009
60. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001; 47:624-30; PMID:11274010
61. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313-27; PMID:17060676; http://dx. doi.org/10.1200/JCO.2006.08.2644
62. Rother M. Carcinoembryonic antigen monitoring for early detection of asymptomatic incurable metastatic colorectal cancer. J Clin Oncol 2007; 25:1293-4; author reply 4; PMID:17401025; http://dx.doi.org/ 10.1200/JCO.2006.10.0974
63. Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, et al. Potent control of tumor growth by CEACD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 2009; 32:341-52; PMID:19342971; http://dx.doi.org/10.1097/CJI.0b013e31819b7c70
64. Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, Lyerly HK, Morse MA. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEACD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer 2010; 102:124-33; PMID:19953093; http://dx.doi.org/10.1038/sj.bjc.6605364
65. Chester KA, Robson L, Keep PA, Pedley RB, Boden JA, Boxer GM, Hawkins RE, Begent RH. Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli. Int J Cancer 1994; 57:67-72; PMID:8150543; http://dx.doi. org/10.1002/ijc.2910570113
66. Jones TD, Hanlon M, Smith BJ, Heise CT, Nayee PD, Sanders DA, Hamilton A, Sweet C, Unitt E, Alexander G, et al. The development of a modified human IFNalpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J Interferon Cytokine Res 2004; 24:560-72; PMID:15450132; http://dx.doi.org/ 10.1089/jir.2004.24.560
67. Brischwein K, Schlereth B, Guller B, Steiger C,Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006; 43:1129-43; PMID:16139892; http://dx.doi.org/10.1016/j. molimm.2005.07.034
68. Bhatnagar J, Tewari HB, Bhatnagar M, Austin GE. Comparison of carcinoembryonic antigen in tissue and serum with grade and stage of colon cancer. Anticancer Res 1999; 19:2181-7; PMID:10472328
69. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A, Verdecchia GM, et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 2006; 12:6985-8; PMID:17145818; http://dx.doi.org/ 10.1158/1078-0432.CCR-06-1931
70. Baeuerle PA, Reinhardt C, Kufer P. BITE: a new class of antibodies that recruit T-cells. Drugs of the Future 2008; 33:137-47; http://dx.doi.org/10.1358/ dof.2008.033.02.1172578
71. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29:1093-102; PMID:19946335; http://dx.doi.org/10.1038/ onc.2009.416
72. Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, et al. Selective targeting and potent control of tumor growth using an EphA2CD3-Bispecific single-chain antibody construct. Cancer Res 2007; 67:3927-35; PMID:17440108; http://dx.doi. org/10.1158/0008-5472.CAN-06-2760
73. Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, Kischel R, Hoffmann P, Brandl C, Schuhmacher J, et al. Regression of human prostate cancer xenografts in mice by AMG 212BAY2010112, a novel PSMACD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 2012; 11:2664-73; PMID:23041545; http://dx. doi.org/10.1158/1535-7163.MCT-12-0042
74. Krupka C, Kufer P, Kischel R, Zugmaier G, Bogeholz J, Kohnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2013; 123:356-65; PMID:24300852; http://dx. doi.org/10.1182/blood-2013-08-523548
75. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308; PMID:17384584; http://dx.doi.org/ 10.1038/nrc2109
76. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-62; PMID:19629070; http://dx. doi.org/10.1038/nrc2664
77. Lutterbuese R, Raum T, Kischel R, Hoffmann P, Mangold S, Rattel B, Friedrich M, Thomas O, Lorenczewski G, Rau D, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci U S A 2010; 107:12605-10; PMID:20616015; http://dx.doi.org/10.1073/pnas.1000976107
78. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15:3184-8; PMID:19366826; http://dx.doi.org/10.1158/1078-0432.CCR-08-2961
79. Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and pairedmetastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 2011; 68:1045-55; PMID:21340604; http://dx.doi.org/10.1007/s00280-011-1586-z
80. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69:1851-7; PMID:19223544; http://dx. doi.org/10.1158/0008-5472.CAN-08-2466
81. Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissiere F, et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer 2009; 100:1330-5; PMID:19367287; http://dx.doi. org/10.1038/sj.bjc.6605008